Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Application Amid ‘New Era’ of Psychedelic Medicine

  • Substances such as psilocybin, ketamine and LSD are edging into mainstream culture, setting the stage for a paradigm shift in modern medicine
  • Cybin has filed an international patent application covering methods for the delivery of psychedelic medications by inhalation
  • The company is pursuing the effectiveness of using inhalation as a delivery method for psychedelic medications

Earlier this month, a Time magazine article reported on the “new era” of psychedelic medicine (https://ibn.fm/bfC3u). On the leading edge of this collective breakthrough is Cybin (NEO: CYBN) (NYSE American: CYBN), a company focused on progressing psychedelic therapeutics, addressing the mental health crisis and transforming the treatment landscape. As part of its mission, the company has filed an international patent application related to delivery methods of psychedelic medications (https://ibn.fm/vaIVQ). 

“As a growing number of states and cities move to decriminalize drugs, and investors flock to an emerging market for psychedelic health care, substances like psilocybin, ketamine and LSD are edging into mainstream culture—and setting the stage for a paradigm shift in modern medicine,” stated the Time article.  “Within the next few years, we could see psychedelic therapies prescribed for refractory depression and post-traumatic stress disorder (‘PTSD’), or used in palliative care among those facing a life-limiting illness. . . . It’s no coincidence that psychedelics are entering the conversation at the moment we most sorely need new ideas in mental health care.”

Committed to finding answers to the growing need for effective mental health care solutions, Cybin has filed an international patent application covering methods for the delivery of psychedelic medications by inhalation as well as devices for performing those methods.

The application, which is governed by the Patent Cooperation Treaty (“PCT”), would give Cybin potential to obtain patent coverage in 153 countries.

“The continued progression of our research programs guides our discovery of new molecules and differentiating treatment approaches,” said Cybin CEO Doug Drysdale. “Continued innovation, as demonstrated by our expanding IP portfolio, positions Cybin as a leading innovator in the development of putative psychedelic treatments for a variety of mental health conditions.”

Based on its research and study, Cybin is pursuing the effectiveness of using inhalation as a delivery method for psychedelic medications. Traditional oral drug administration presents certain challenges that CYBN believes can be alleviated through inhalation of the psychedelic substance. Specifically, the company reports, it expects inhalation delivery to facilitate optimized psychedelic session timing compared to oral administration of the same compounds, lower doses of psychedelic therapeutics while preserving efficacy, and providing health care providers with more control during psychedelic sessions.

The patent was filed in support of Cybin’s CYB004 preclinical development program. The patent would increase the company’s library of drug-delivery modalities focused on optimal delivery of psychedelics and strengthen Cybin’s growing IP portfolio. The filing also includes support for future research programs the company may undertake, including those exploring various ways to reduce or minimize negative side effects in psychedelic psychotherapy patients. The company may also look at ways to lower medication doses without impacting treatment efficacy while increasing the long-term efficacy of psychedelic sessions.

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN 

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Archives

Select A Month

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050